Cetirizine drip for treating acute urticaria is as effective as intravenous diphenhydramine, with the added benefits of less sedation, fewer adverse events, shorter treatment time, and lower rates of revisit to treatment centre, according to the results of a phase III study.
Treatment with clascoterone cream 1% results in a favourable safety profile, with a low frequency of treatment-emergent adverse events (TEAEs) over 9 months, in patients with acne vulgaris, results of a recent study have shown.
The type I interferon receptor antibody anifrolumab reduced disease activity and flares in patients with moderate-to-severe active systemic lupus erythematosus (SLE), results of the TULIP-1 and TULIP-2 trials have shown.
Upadacitinib may be a suitable treatment for patients with active psoriatic arthritis (PsA) who have insufficient response to non-biologic disease-modifying anti-rheumatic drugs (non-bDMARDs), according to results of the phase III SELECT-PsA-1* trial presented at EULAR 2020.
Brodalumab, risankizumab, and ixekizumab rank as the top three best performing biologic drugs for psoriasis, yielding the highest rates of complete clearance of lesions and scoring a high probability of being the most effective in the induction treatment phase, according to the results of a network meta-analysis.
Adjuvant treatment with dabrafenib plus trametinib prolongs relapse-free survival (RFS) in patients with resected stage III BRAF V600-mutant melanoma, according to a 5-year analysis of the COMBI-AD* study presented at the ASCO20 Virtual Scientific Program.
In the face of the COVID-19 pandemic which has taken the world by storm, the lack of approved treatments targeted towards coronavirus has left physicians worldwide grappling with the situation. To help them navigate the black box of COVID-19 management, the ACP* has released a behemoth 28-chapter guide to arm physicians in the virus-infested battle field.
In patients with heart failure with reduced ejection fraction (HFrEF) receiving angiotensin-converting-enzyme (ACE) inhibitors, high dosing confers benefits for the risk of death or hospitalization that are similar to that obtained with lower dosing, according to a systematic review and meta-analysis.